GLI1 and breast neoplasm: To determine the sensitivity of breast tumor cells to Hh inhibitors, expression levels of Hh pathway components and cell growth were evaluated in response to exogenous addition of SHH-ligand, SMO, and GLI1 inhibitors, NVP-LDE225 (NVP) and GANT61, respectively.